MX360787B - Metodos para reducir neurodegeneracion. - Google Patents

Metodos para reducir neurodegeneracion.

Info

Publication number
MX360787B
MX360787B MX2013014430A MX2013014430A MX360787B MX 360787 B MX360787 B MX 360787B MX 2013014430 A MX2013014430 A MX 2013014430A MX 2013014430 A MX2013014430 A MX 2013014430A MX 360787 B MX360787 B MX 360787B
Authority
MX
Mexico
Prior art keywords
methods
day
neurodegeneration
melatonin
reducing
Prior art date
Application number
MX2013014430A
Other languages
English (en)
Other versions
MX2013014430A (es
Inventor
Paul Middleton Rondo
Michael Zanghi Brian
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013014430A publication Critical patent/MX2013014430A/es
Publication of MX360787B publication Critical patent/MX360787B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/184—Hormones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/168—Steroids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a una cantidad de melatonina que reduzca neurodegeneración para usarse para reducir neurodegeneración en un canino, en donde la melatonina es administrable en cantidades de 1ng/kg/día a 2 mg/kg/día. La cantidad de melatonina que reduzca neurodegeneración para usarse en donde la melatonina es administrable en una composición comestible, como por ejemplo una composición de alimento.
MX2013014430A 2011-06-08 2012-06-04 Metodos para reducir neurodegeneracion. MX360787B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161520332P 2011-06-08 2011-06-08
PCT/US2012/040658 WO2012170322A1 (en) 2011-06-08 2012-06-04 Methods for reducing neurodegeneration

Publications (2)

Publication Number Publication Date
MX2013014430A MX2013014430A (es) 2014-01-20
MX360787B true MX360787B (es) 2018-11-16

Family

ID=47296378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014430A MX360787B (es) 2011-06-08 2012-06-04 Metodos para reducir neurodegeneracion.

Country Status (12)

Country Link
US (1) US20140113949A1 (es)
EP (1) EP2717695B1 (es)
JP (1) JP6284473B2 (es)
CN (1) CN103582421A (es)
AU (1) AU2012268562B2 (es)
BR (1) BR112013031460A2 (es)
CA (1) CA2838461C (es)
ES (1) ES2605454T3 (es)
MX (1) MX360787B (es)
RU (1) RU2013158254A (es)
WO (1) WO2012170322A1 (es)
ZA (1) ZA201400115B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331313A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人p70核糖体S6激酶11.77和编码这种多肽的多核苷酸
AU2003230644A1 (en) * 2002-03-14 2003-09-29 Ercole L. Cavalieri A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
AU2003259803B2 (en) * 2002-08-12 2007-08-02 The Regents Of The University Of Michigan Diagnosis and treatment of tuberous sclerosis
US7361681B2 (en) * 2003-03-28 2008-04-22 Sygnis Bioscience Gmbh & Co. Kg Method of treating amytrophic lateral sclerosis using melatonin
JP4993900B2 (ja) * 2005-11-28 2012-08-08 国立大学法人 東京医科歯科大学 記憶障害抑制剤
ES2703571T3 (es) * 2008-03-27 2019-03-11 Nestec Sa Métodos para aumentar la absorción de péptidos, peptidomiméticos y otros sustratos de proteína de transporte gastrointestinal

Also Published As

Publication number Publication date
JP2014518899A (ja) 2014-08-07
CA2838461A1 (en) 2012-12-13
MX2013014430A (es) 2014-01-20
AU2012268562B2 (en) 2016-06-16
AU2012268562A1 (en) 2013-12-19
ZA201400115B (en) 2015-11-25
US20140113949A1 (en) 2014-04-24
ES2605454T3 (es) 2017-03-14
CN103582421A (zh) 2014-02-12
JP6284473B2 (ja) 2018-02-28
CA2838461C (en) 2019-12-03
EP2717695B1 (en) 2016-11-02
EP2717695A1 (en) 2014-04-16
WO2012170322A1 (en) 2012-12-13
EP2717695A4 (en) 2014-06-18
BR112013031460A2 (pt) 2016-08-16
RU2013158254A (ru) 2015-07-20

Similar Documents

Publication Publication Date Title
UA110354C2 (uk) Противірусні сполуки
MX341739B (es) Compuestos de dihidroisoxazol parasiticidas.
UA115532C2 (uk) Модулятори нуклеарного транспорту, що містять гідразид, і їхнє застосування
EP2415749A4 (en) NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE
MX2014001180A (es) Moduladores del transporte nuclear y usos de los mismos.
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
SG190785A1 (en) Antiviral compounds
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
IN2014CN04773A (es)
IN2013DN02555A (es)
MX2013004878A (es) N-hetarilmetil pirazolilcarboxamidas.
MX2013013098A (es) Metodos y composiciones para fomentar el crecimiento de la masa corporal magra.
IN2014DN03010A (es)
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
IN2014KN00865A (es)
MX2013014430A (es) Metodos para reducir neurodegeneracion.
WO2010093615A3 (en) Compounds, their syntheses, compositions, and methods to treat cancer
TW201613606A (en) Therapeutic drug for chronic renal failure

Legal Events

Date Code Title Description
FG Grant or registration